You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Anixa Biosciences completes dosing of fourth cohort in ovarian cancer CAR-T trial; Early results show promise
Login
Username:

Password:


Related Headlines

IDEAYA Biosciences and Hengrui Pharma announce IDE849 (SHR-4849) positive Phase 1 data in small cell lung cancer at IASLC 2025 World Conference on Lung Cancer

Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor

Blue Cell Therapeutics appoints Olav Hellebo as board chairman

IDEAYA Biosciences enrols first patient in Phase 1/2 trial of IDE397 and Trodelvy for MTAP-deletion non-small cell lung cancer

ExpreS2ion reports early immune response in first patient from Phase I HER2 breast cancer vaccine trial

enGene completes target enrollment for LEGEND pivotal cohort

IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025

Karyopharm Therapeutics awards inducement grants to new employees

RaySearch introduces RayIntelligence v2025 to enhance oncology analytics

ImmuPharma files patent for P140 'Immunormalizer' with precision diagnostic for autoimmune diseases

Avacta completes sale of Coris Bioconcept to 3B BlackBio Dx

YD Bio closes business combination and listing on Nasdaq Global Market

BeOne Medicines reports positive topline data for sonrotoclax in mantle cell lymphoma

NeoGenomics wins court ruling invalidating Natera patent claims

Thor Medical and Oncoinvent sign thorium-228 supply deal for cancer therapy development

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025